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Abstract: Many antimicrobial peptides (AMPs) have been identified from the skin secretion of the
frog Hylarana guentheri (H. guentheri), including Temporin, Brevinin-1, and Brevinin-2. In this study,
an antimicrobial peptide named Brevinin-1GHa was identified for the first time by using ‘shotgun’
cloning. The primary structure was also confirmed through mass spectral analysis of the skin secretion
purified by reversed-phase high-performance liquid chromatography (RP-HPLC). There was a
Rana-box (CKISKKC) in the C-terminal of Brevinin-1GHa, which formed an intra-disulfide bridge.
To detect the significance of Rana-box and reduce the hemolytic activity, we chemically synthesized
Brevinin-1GHb (without Rana-box) and Brevinin-1GHc (Rana-box in central position). Brevinin-1GHa
exhibited a strong and broad-spectrum antimicrobial activity against seven microorganisms, while
Brevinin-1GHb only inhibited the growth of Staphylococcus aureus (S. aureus), which indicates
Rana-box was necessary for the antimicrobial activity of Brevinin-1GHa. The results of Brevinin-1GHc
suggested transferring Rana-box to the central position could reduce the hemolytic activity, but the
antimicrobial activity also declined. Additionally, Brevinin-1GHa demonstrated the capability of
permeating cell membrane and eliminating biofilm of S. aureus, Escherichia coli (E. coli), and Candida
albicans (C. albicans). The discovery of this research may provide some novel insights into natural
antimicrobial drug design.
Keywords: amphibian; antimicrobial; peptides; Brevinin-1; Rana-box
Key Contribution: A novel strong and broad-spectrum antimicrobial peptide Brevinin-1GHa was
firstly identifiedfrom the skin secretion of H. guentheri.
1. Introduction
On account of the widespread use and misuse of antibiotics during the past decades, there is an
alarming emergence of strains of pathogenic bacteria and fungi that are resistant to a range of formerly
conventionally used effective antibiotics, which have posed a severe global threat to public health [1–4].
As a result, there is an urgent need for some entirely novel types of antimicrobial agents which has
clear pharmacokinetics and toxicology [5].
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A big-sized frog Hylarana guentheri, which is widely distributed and the dominating amphibian
species in Southern China, belongs to the genus Hylarana within the family Ranidae [6,7]. To adapt
to specific environments, the skin secretion of H. guentheri contain abundant types of antimicrobial
peptides(AMPs), and according to the structural characteristics, most of them belong to Brevinin-1,
Brevinin-2, and Temporin families [8].
The first identified Brevinin-1 peptide was isolated from the skin of Rana brevipoda porsa and
contained 24 amino acid residues [9]. Then some researches revealed some common structural features
of Brevinin-1 family, Proline is often the 14th residue in the sequence [10], and most of them have a cyclic
heptapeptide (Cys18-(Xaa)4-Lys-Cys24) called Rana-box at the C-terminal, which forms a disulfide
bridge [11]. Brevinin-1 peptides usually demonstrate a broad-spectrum antimicrobial activity against
Gram-positive and Gram-negative bacteria and strains of pathogenic fungi [9], and some analogues can
inhibit the growth of cancer cell lines [12]. Peptides in the Brevinin-1 family are linear, amphipathic and
cationic. Cationic amino acids can facilitate the interaction of peptides with the bacterial membranes
and the negatively charged cell membranes through electrostatic attraction [13]. In the hydrophobic
membrane-mimetic environment, Brevinin-1 peptides exist as an amphipathic α-helical structure that
perturbs the phospholipid bilayer to combine well with targeted membranes [14].
In the present study, a novel peptide named Brevinin-1GHa was isolated from the skin secretion
of H. guentheri. The primary structure was obtained via ‘shotgun’ cloning and confirmed by mass
spectrum (MS/MS) fragmentation sequencing. Also, Brevinin-1GHb (without Rana-box) was designed
to test the significance of Rana-box for the antimicrobial activity and Brevinin-1GHc (Rana-box in
the central position) was designed to reduce the hemolytic activity. Both Brevinin-1GHa and its two
analogues were chemically synthesized by solid phase peptide synthesis and the second structures
were predicted by online analysis tools. Subsequently, the synthetic peptides were subjected to
antimicrobial and hemolysis assay to determinate their bioactive functions. On account of the strong
antimicrobial activity of Brevinin-1GHa, more tests were carried, including time-killing curves, cell
membrane permeability assay, and anti-biofilm assay.
2. Results
2.1. ‘Shotgun’ Cloning of a Novel Peptide Precursor-Encoding cDNA and Bioinformatic Analyses
A full-length cDNA, encoding Brevinin-1GHa, was successfully cloned from the skin secretion
–derived cDNA library of H. guentheri. The sequence of nucleotide and translated open reading frame
amino acids are shown in Figure 1. There were several typical structural characteristics, including a
putative signal peptide region of 22 amino acid residues, an acidic spacer peptide region, a classical
-KR- propeptide convertase processing site, a mature peptide of 24 amino acid residues and a Rana-box
at the C-terminal. The nucleotide sequence of Brevinin-1GHa precursor was deposited in the Genbank
Nucleotide Sequence Database under the accession number MH791156.
The putative mature peptide was subjected to bioinformatics analysis by use of the National
Center for Biotechnology Information (NCBI) protein Basic Local Alignment Search Tool (BLAST)
program, which found that Brevinin-1GHa was a new Brevinin-1. The alignment demonstrated
that Brevinin-1GHa owned at least eight different amino acid residues from others and showed 67%
degree of structural identity to other Brevinin-1 peptides. Besides, the predicted secondary structures
indicated Brevinin-1GHa had the highest proportion of α-helix among its homologs, as shown in
Table 1.
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Figure 1. Nucleotide and translated open-reading frame amino acid sequence of a cDNA encoding 
the biosynthetic precursor of a novel Brevinin-1GHa from H. guentheri. The signal peptide is double-
underlined, the mature peptide is single-underlined, and the stop codon is indicated by an asterisk. 
The Rana-box was indicated in the red boxes. 
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Peptide Name Source Amino Acid Sequence Alpha Helix Identities 
Brevinin-1GHa Hylarana guentheri 
1FLGAVLKVAGKLVPAAICKISKKC24 
chhhhhhhhhhhhhhhhhhhhccc 
83.33%  
Brevinin-1HSa Odorrana hosii 
1FLPAVLRVAAKIVPTVFCAISKKC24 
cchhhhhhhhhhccceeeeecccc 
41.67% 67% 
Brevinin-1WY7 Amolops wuyiensis 
47FLGSILGLVGKVVPTLICKISKKC70 
cchhhhhhhhhhchheeeeecccc 
50.00% 67% 
Brevinin-1WY5 Amolops wuyiensis 
48FLGSLLGLVGKVVPTLICKISKKC71 
chhhhhhhhcccecceeeeeecccc 
29.17% 67% 
Brevinin-1JDc 
Odorrana 
jingdongensis 
1FLPAVLRVAAKVVPTVFCLISKKC24 
cchhhhhhhhhhccceeeeeeccc 
41.67% 67% 
Brevinin-1RTc Amolops ricketti 
48FLGSLLGLVGKIVPTLICKISKKC71 
chhhhhhhhhcecheeeeeecccc 
41.67% 67% 
Brevinin-1LTd Sylvirana latouchii 
48FFGSVLKVAAKVLPAAICQIFKKC71 
cchhhhhhhhhhhhhhhhhhhhcc 
83.33% 67% 
The secondary structures of peptides were predicted by the online HNN program (http://npsa-
prabi.ibcp.fr/cgi-bin/npsa_automat.pl?page=/NPSA/npsa_hnn.html). ‘h’ indicates α-helix, ‘c’ 
indicates random coil and ‘e’ indicates extended strand. 
2.2. Fractionation of Skin Secretion, Identification, and Structural Characterisation of Brevinin-1GHa 
The lyophilized crude skin secretion of H. guentheri was fractioned by reversed-phase high-
performance liquid chromatography (RP-HPLC), as shown in Figure 2A. The arrow indicated the 
retention times/elution position of the peptide with the mass coincident with the approximate 
Figure 1. Nucleotide and translated open-reading frame amino acid sequence of a cDNA encoding
the biosynthetic precursor of a novel Brevinin-1GHa from H. guentheri. The signal peptide is
double-underlined, the mature peptide is single-underlined, and the stop codon is indicated by
an asterisk. The Rana-box was indicated in the red boxes.
Table 1. Primary and secondary structural comparison of Brevinin-1GHa with relevant antimicrobial
peptides (AMPs) homologs.
Peptide Name Source Amino Acid Sequence Alpha Helix Identities
Brevinin-1GHa Hylarana guentheri
1FLGAVLKVAGKLVPAAICKISKKC24
chhhhhhhhhhhhhhhhhhhhccc
83.33%
Brevinin-1HSa Odorran hosii
1FLPAVLRVAAKIVPTVFCAISKKC24
cchhhhhhhhhhccceeeeecccc
41.67% 67%
Brevinin-1WY7 Amolops wuyiensis
47FLGSILGLVGKVVPTLICKISKKC70
cchhhhhhhhhhchheeeeecccc
50.00% 67%
Brevinin-1WY5 Amolops wuyiensis
48FLGSLLGLVGKVVPTLICKISKKC71
chhhhhhhhcccecceeeeeecccc
29.17% 67%
Brevinin-1JDc Odorranajingdongensis
1FLPAVLRVAAKVVPTVFCLISKKC24
cchhhhhhhhhhccceeeeeeccc
41.67% 67%
Brevinin-1RTc Amolops ricketti
48FLGSLLGLVGKIVPTLICKISKKC71
chhhhhhhhhcecheeeeeecccc
41.67% 67%
Brevinin-1LTd Sylvirana latouchii
48FFGSVLKVAAKVLPAAICQIFKKC71
cchhhhhhhhhhhhhhhhhhhhcc
83.33% 67%
The secondary structures of peptides were predicted by the online HNN program (http://npsa-prabi.ibcp.fr/
cgi-bin/npsa_automat.pl?page=/NPSA/npsa_hnn.html). ‘h’ indicates α-helix, ‘c’ indicates random coil and ‘e’
indicates extended strand.
2.2. Fractionation of Skin Secretio , Identification, and Structural Characterisation of Brevinin-1GHa
The lyophilized crude skin secretion of H. guentheri was fractioned by reversed-phase
high-performance liquid chromatography (RP-HPLC), as shown in Figure 2A. The arrow indicated
the retention times/elution position of the peptide with the mass coincident with the approximate
predicted molecular mass of Brevinin-1GHa. The amino acid sequence of Brevinin-1GHa, as further
determined by MS/MS sequencing, is shown in Figure 2B.
Toxins 2018, 10, 413 4 of 16
Toxins 2018, 10, x FOR PEER REVIEW  4 of 16 
 
predicted molecular mass of Brevinin-1GHa. The amino acid sequence of Brevinin-1GHa, as further 
determined by MS/MS sequencing, is shown in Figure 2B. 
A 
 
B 
 
Figure 2. (A) RP-HPLC of skin secretion of Hylarana guentheri at a wavelength of 214 nm. The abscissa 
was ‘retention time (min)’, and the ordinate ‘AU’ was ‘absorbance’. The arrow indicated the retention 
time of Brevinin-1GHa., . (B) Predicted b-ion and y-ion MS/MS fragment ion series (singly- and 
doubly-charged) of Brevinin-1GHa. The actual ions detected in MS/MS spectra are colored red and 
blue. #1, the sequence from N-terminal to C-terminal; b(1+) and b(2+), singly- and doubly-charged b-
ions; Seq.,the sequence of amino acid residues. y(1+) and y(2+), singly- and doubly-charged y-ions; #2, 
the sequence from C-terminal to N-terminal . 
2.3. Solid Phase Peptide Synthesis (SPPS) of Brevinin-1GHa, Brevinin-1GHb, and Brevinin-1GHc 
Figure 2. (A) RP-HPLC of skin secretion of Hylarana guentheri at a wavelength of 214 nm. The
abscissa was ‘retention time (min)’, and the ordinate ‘AU’ was ‘absorbance’. The arrow indicated the
retention time of Brevinin-1GHa., (B) Predicted b-ion and y-ion MS/MS fragment ion series (singly-
and doubly-charged) of Brevinin-1GHa. The actual ions detected in MS/MS spectra are colored red
and blue. #1, the sequence from N-terminal to C-terminal; b(1+) and b(2+), singly- and doubly-charged
b-ions; Seq., the sequence of amino acid residues. y(1+) and y(2+), singly- and doubly-charged y-ions;
#2, the sequence from C-terminal to N-terminal.
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2.3. Solid Phase Peptide Synthesis (SPPS) of Brevinin-1GHa, Brevinin-1GHb, and Brevinin-1GHc
After the determination of the primary structure of Brevinin-1GHa (FLGAVLKVAGKLVP
AAICKISKKC), the peptide was successfully synthesized by applying a solid phase Fmoc chemical
method. As some research about Brevinin-1 family peptides found, the C-terminal cyclic heptapeptide
domain can be replaced by a C-terminally-amidated residue, it suggested the Rana-box may not
be crucial for the antimicrobial activity of peptides [15]. To detect whether “Rana-box” plays an
important role in the antimicrobial function of Brevinin-1GHa or not, we designed and synthesized a
novel peptide Brevinin-1GHb (FLGAVLKVAGKLVPAAI). In addition, the research about Brevinin-1E
suggested transferring the C-terminal Rana-box to central position led to a considerable reduction
of Brevinin-1E’s hemolytic activity without loss of antibacterial activity [16], so Brevinin-1GHc
(FLGAVLKVCKISKKCAGKLVPAAI) was designed and synthesized. All synthetic peptides were
subjected to RP-HPLC to determine the degree of purity and MALDI-TOF to establish the authenticity
of the structure.
2.4. Secondary Structure Prediction of Brevinin-1GHa, Brevinin-1GHb, and Brevinin-1GHc
The helical wheel plots and secondary structures were predicted by online analysis tools. The
result showed that Brevinin-1GHa carried +5 net charge with the hydrophobicity of 0.592 and the
hydrophobic moment of 0.358. Brevinin-1GHa also had a hydrophobic face consisted of A,A,L,I,V.
Moreover, the predicted secondary structure contained a large proportion of the α-helical domain with
a high C-score. Similarly, a three-dimensional simulation of Brevinin-1GHa exhibited the structural
characteristics of α-helix, as shown in Figure 3A. Brevinin-1GHb only possessed two positive charges,
with the hydrophobicity of 0.725 and the hydrophobic moment of 0.420. Different from Brevinin-1GHa,
Brevinin-1GHb did not contain a hydrophobic face, and the length of α-helix is much shorter as shown
in Figure 3B. Brevinin-1GHc owned five positive net charges, with the hydrophobicity of 0.592 and
the hydrophobic moment of 0.373. Compared with Brevinin-1GHa, Brevinin-1GHc had a shorter
hydrophobic face consisted of V,A,A, as shown in Figure 3C.
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2.5. Antimicrobial and Hemolytic Activities of Brevinin-1GHa, Brevinin-1GHb, and Brevinin-1GHc
To detect the antimicrobial activities of three synthesized peptides, we used S. aureus; Enterococcus
faecalis (E. faecalis); methicillin-resistant Staphylococcus aureus (MRSA); E. coli; Pseudomonas aeruginosa
(P. aeruginosa); Klebsiella pneumoniae (K. pneumoniae) and the yeast C. albicans. The results showed
Brevinin-1GHa exhibited a potent broad-spectrum antimicrobial activity against all seven tested
microorganisms. Brevinin-1GHb only showed the inhibition on S. aureus with the concentration
at 512 µM. Brevinin-1GHc also inhibited the growth of seven microorganisms, but the efficacy is
much lower than Brevinin-1GHa. The minimum inhibitory concentrations (MICs) and minimum
bactericidal concentrations (MBCs) obtained with three peptides are shown in Table 2. Brevinin-1GHa,
Brevinin-1GHb, and Brevinin-1GHc exhibited a hemolysis rate near 20% on horse erythrocytes with
the concentration at 16, 512, and 128 µM, respectively, as shown in Figure 4.
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Table 2. Minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs)
of Brevinin-1GHa, Brevinin-1GHb, and Brevinin-1GHc against seven different microorganisms
Microorganisms
Brevinin-1GHa Brevinin-1GHb Brevinin-1GHc
MIC (µM) MBC (µM) MIC (µM) MBC (µM) MIC (µM) MBC (µM)
Gram-positive
S. aureus 2 2 512 >512 32 32
E. faecalis 8 16 >512 >512 128 128
MRSA 4 4 >512 >512 128 128
Gram-negative
E. coli 4 8 >512 >512 16 32
P. aeruginosa 32 64 >512 >512 128 512
K. pneumoniae 8 16 >512 >512 256 512
yeast C. albicans 2 4 >512 >512 128 128
Toxins 2018, 10, x FOR PEER REVIEW  7 of 16 
 
Table 2. Minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) 
of Brevinin-1GHa, Brevinin-1GHb, and Brevinin-1GHc against seven different microorganisms 
Microorganisms 
Brevinin-1GHa Brevinin-1GHb Brevinin-1GHc 
IC (µM) MBC (µM) MIC (µM) MBC (µM) MIC (µM) MBC (µM) 
Gram-positive 
 reus 2 2 512 >512 32 32 
E. faecalis 8 16 >512 >512 128 128 
MRSA 4 4 >512 >512 128 128 
Gram-negative 
E. coli 4 8 >512 >512 16 32 
P. aeruginosa 32 64 >512 >512 128 512 
K. pneumoniae 8 16 >512 >512 256 512 
yeast C. albicans 2 4 >512 >512 128 128 
 
Figure 4. Hemolytic activity of Brevinin-1GHa, Brevinin-1GHb, and Brevinin-1GHc on horse 
erythrocytes. 
2.6. Time-Killing Assay of Brevinin-1GHa against S. aureus, E. coli, and C. albicans 
Brevinin-1GHa with the concentration at 1× MIC inhibited the growth of S. aureus markedly 
during 20–40 min. Surviving cells could not be counted after 40 min, while it showed a recovery rate 
after 90 min. 2 and 4× MIC of Brevinin-1GHa killed bacterial to an uncountable state at 15 and 10 min, 
respectively, as shown in Figure 5A. E. coli was killed steadily by Brevinin-1GHa with concentration 
at 1× MIC during 360 min, and no bacterial was counted after 20 min treated with 2× MIC of Brevinin-
1GHa. 4× MIC of Brevinin-1GHa inhibited the growth to an uncountable state at 10 min, as shown in 
Figure 5B. Similarly, C. albicans was reduced steadily by 1× MIC of Brevinin-1GHa. Treated with 2 
and 4× MIC of Brevinin-1GHa, no yeast was counted at 60 and 10 min respectively, as shown in Figure 
5C. 
 
4. Hemolytic activi y of Brevinin-1GHa, Brevinin-1GHb, and Brevinin-1GHc on horse erythrocytes.
2.6. Time-Killing Assay of Brevinin-1GHa against S. aureus, E. coli, and C. albicans
Brevinin-1GHa with the concentration at 1× MIC inhibited the growth of S. aureus markedly
during 20–40 min. Surviving cells could not be counted after 40 min, while it showed a recovery
rate after 90 min. 2 and 4× MIC of Brevinin-1GHa killed bacterial to an uncountable state at 15
and 10 min, respectively, as shown in Figure 5A. E. coli was killed steadily by Brevinin-1GHa with
concentration at 1×MIC during 360 min, and no bacterial was counted after 20 min treated with 2×
MIC of Brevinin-1GHa. 4×MIC of Brevinin-1GHa inhibited the growth to an uncountable state at
10 min, as shown in Figure 5B. Similarly, C. albicans was reduced steadily by 1×MIC of Brevinin-1GHa.
Treated with 2 and 4×MIC of Brevinin-1GHa, no yeast was counted at 60 and 10 min respectively, as
shown in Figure 5C.
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4×MIC. (A) S. aureus; (B) E. coli; (C) C. albicans.
2.7. Cell-M mbrane Perm abilization Assay of Brevinin-1G i st S. aureus, E. coli, and C. albicans
Brevinin-1GHa did not cause the significant cell-membrane permeabilization of S. aureus with
the concentration at 2 µM (1× MIC). While it showed the permeability rate at 20% and 90% with
the concentration at 4 µM (2× MIC) and 8 µM (4× MIC), respectively, as shown in Figure 6A.
Brevinin-1GHa only caused near 30% permeability rate of E. coli with the concentration at 16 µM (4×
MIC), as shown in Figure 6B. Also, 8 µM (4×MIC) of Brevinin-1GHa disrupted the cell membrane of
C. albicans, as shown in Figure 6C.
2.8. Anti-Biofilm Assay of Brevinin-1GHa against S. aureus, E. coli, and C. albicans
Brevinin-1GHa was able to suppress the biofilm formation of S. aureus, E. coli, and C. albicans
broadly with the minimum biofilm inhibitory concentration (MBIC) at 4, 32, and 2 µM, respectively.
Brevinin-1GHa could also eliminate the already formed biofilms with the minimal biofilm eradication
concentration (MBEC) at 16 µM against S. aureus, 64 µM against E. coli and 8 µM against C. albicans, as
shown in Table 3.
Table 3. Anti-biofilm activity of Brevinin-1GHa against the biofilm of S. aureus, E. coli, and C. albicans
Microorganisms S. aureus E. coli C. albicans
MBIC (µM) 4 32 2
MBEC (µM) 16 64 8
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Figure 6. Cell-membrane permeability effects of Brevinin-1GHa on S. aureus (A); E. coli (B); C. albicans
(C). Peptide concentrations corresponded to 1×, 2×, and 4×MIC. The positive controls were treated
with 70% isopropanol, and the negative controls were represented as the vehicle only. (t-test of each
individual concentration contrast with negative control group, * p < 0.05, *** p < 0.001).
3. Discussion
Amphibians are the first group that bridges the evolutionary water−land gap and forced to face
the dangerous enviro ent including pathogenic microorga isms, predators, parasites, and physical
factors. To adapt to the changing environm nt, amphibian skin which directly exposes to the outside
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world endowed with excellent chemical defense strategies. Lots of studies have proved that the skin
secretion of amphibian can provide a significant amount of valuable information about prospective
bioactive components, such as peptides, proteins, and alkaloids [17].
In this study, we cloned and purified a novel antimicrobial peptide from the skin secretion of
H. guentheri. The amino acid sequence of Brevinin-1GHa was submitted to the BLAST program
for the comparison of homology. The result revealed that the primary structure of Brevinin-1GHa
is 67% identical to Brevinin-1HSa from Odorranahosii, Brevinin-1WY7 and Brevinin-1WY5 from
Amolopswuyiensis, as well as Brevinin-1JDc from Odorranajingdongensis, as shown in Table 1. According
to the UNIPORT database, only Brevinin-1HSa and Brevinin-1JDc’s bioactive functions have been
detected; the results are shown in Table 4. Both Brevinin-1GHa and Brevinin-1JDc have demonstrated
potent antimicrobial activities against the Gram-positive, Gram-negative and fungi tested, which
may due to the strongly conserved structure formed by the Phe1, Ala9, Val13, and Pro14 residues [18].
The bacterial cell membrane is composed mainly of negatively charged phosphatidylglycerol and
lipopolysaccharides. Therefore, the residues carried with the positive net charge in peptides
are considered to play a significant role in binding to the phospholipid head groups in the cell
membrane [19]. Then AMPs form hundreds of transient transmembrane pores that cause the leakage
of small molecular mass molecules to facilitate the collapse of the cell membrane [20]. The 14th amino
acid residue Proline of peptides in Brevinin-1 family produces a stable kink structure, which lets
peptides be more likely to fasten on the zwitterionic membrane and facilitates the lysis of bacterial
cell [21]. It explains why Proline is invariant but still exists in most of the Brevinin-1 peptides. Besides
Pro14, the antimicrobial activities of AMPs against bacterial and fungi are determined by a complicated
interaction between the grand average of hydropathicity (GRAVY), the theoretical isoelectric point
(pI), cationicity, α-helix, hydrophobicity, and amphipathicity [22]. Although Brevinin-1GHa and
Brevinin-1JDc show similar antimicrobial spectrum against Gram-positive and Gram-negative bacteria
and fungi, Brevinin-1GHa inhibited the growth of both S. aureus (MIC = 2 µM), E. coli (MIC = 4 µM),
and C. albicans (MIC = 2 µM) more effectively than Brevinin-1JDc. The difference may result from
the increase in cationicity (Brevinin-1GHa pI = 9.90; Brevinin-1JDc pI = 9.85), which boosts the
interaction with the cell membrane with a negative net charge and hence the antimicrobial activity
of Brevinin-1GHa. With the highest net charge at +5, Brevinin-1GHa also owns an extremely high
α-helix proportion at 83.33%; the amphipathic α-helix can destroy plasma membranes rapidly upon
peptides associated with lipid cell membranes. In the end, hydrophobicity is an essential effector
of antimicrobial activities as well. Brevinin-1GHa has the lowest hydrophobicity among peptides
listed in Table 4, while just in the optimal hydrophobicity window could strong antimicrobial activity
be obtained, higher hydrophobicity not only causes decreased antimicrobial activity, but also high
hemolytic activity [23,24]. The reasonable explanation is strong peptide self-association occurs with
high peptide hydrophobicity. It prevents peptides from passing through the cell membranes of
prokaryotic cells but does not influence on eukaryotic cell walls [23].
Table 4. Structural parameters and minimum inhibitory concentrations (MICs) of Brevinin-1GHa and
relevant AMPs homologs against specified microorganisms
Peptide Name GRAVY pI
Net
Charge <H> <µH>
Antimicrobial Activity (MIC µM)
S. aureus E. coli C. albicans MRSA
Brevinin-1GHa 1.054 9.90 +5 0.592 0.358 2 4 2 4
Brevinin-1HSa 1.262 9.85 +4 0.728 0.377 3 24 ND ND
Brevinin-1JDc 1.333 9.85 +4 0.761 0.366 6 49 3 3
Brevinin-1WY7 1.183 9.70 +4 0.736 0.420 ND ND ND ND
GRAVY, grand average of hydropathicity; pI, theoretical isoelectric point. GRAVY and pI were calculated by the
online ProtParam tool (http:web.expasy.org/protparam) [25]. <H>, hydrophobicity; <µH>, hydrophobic moment;
Net charge, <H> and <µH> were calculated by the online analysis tool, HeliQuest (http://heliquest.ipmc.cnrs.fr)
[26]. ND, not detected. MICs came from publications [27,28].
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Rana-box was thought to play a crucial role for antibacterial activities of peptides in Brevinin-1
family until the discovery of C-terminal truncated Brevinin-1 family peptide from Rana okinavana. The
linear acetamidomethylcysteinyl analogue retaining its antibacterial activities indicates the disulfide
bridge is not necessary for high potency [15]. Recent research has reported Brevinin-1RTa, and
Brevinin-1RTb with Rana-box have weak inhibitory effects against Gram-negative bacteria [29]. To test
whether Rana-box is significant for the antimicrobial activities of Brevinin-1GHa, Brevinin-1GHb was
synthesized by SPPS without the disulfide bridge. Compared with Brevinin-1GHa, Brevinin-1GHb
has a lower net charge at +2, a higher hydrophobicity at 0.725, and shorter length of the α-helix
structure as the cut of Rana-box. All changes lead to the loss of antimicrobial activity, whereas the
decrease in hemolytic activity. The decline in the inhibition of bacteria and fungi growth proves
that Rana-box which provided the positive net charge plays a necessary role in the antimicrobial
activities of Brevinin-1GHa. Contrast with higher hydrophobicity causing high hemolytic activity,
Brevinin-1GHb without a hydrophobic face does not show hemolytic activity at a concentration of
256 µM. It indicates the hemolytic activity of peptides is not only related to the hydrophobicity, but
also the hydrophobic face. As reported, transferring the Rana-box from C-terminal to central position
leads to a considerable reduction of Brevinin-1E’s hemolytic activity without loss of antibacterial
activity [14,16], so Brevinin-1GHc was designed and synthesized. The results revealed that the
hemolytic activity increased dramatically at the concentration with 128 µM which is much lower
than Brevinin-1GHa, while the antimicrobial activity was declined as well. The differences of
physicochemical parameters between Brevinin-1GHa and Brevinin-1GHc are the hydrophobic moment
(Brevinin-1GHa = 0.358; Brevinin-1GHc = 0.373) and the length of α-helix (Brevinin-1GHa = 83.33%;
Brevinin-1GHc = 54.17%). It suggested the reduction of hemolytic activity and antimicrobial activity
may mainly due to the decrease of α-helix length.
There are many antibacterial mechanisms, and the most widely accepted one is based on
non-specific interaction with the membrane with the models, like barrel-stave mode, carpet mode,
and toroidal mode [20,30,31]. According to the results of time-killing curves and the cell membrane
permeability assay, the mechanism may be different between low and high concentration, which
agreed with a previous publication [32]. With the low concentrations (1×MIC and 2×MIC) against
S. aureus and C. albicans, Brevinin-1GHa may only cover a limited range of membrane leading to the
formation of limited numbers or sizes of pores, while it nearly fully permeabilized cell membranes
with the high concentration at 4×MIC. In addition, the membrane of E. coli was not destroyed, even
with 4×MIC. The reasonable explanation is Gram-negative bacteria have an extra outer cell membrane
with a large amount of highly negatively-charged lipopolysaccharide, so it becomes more difficult
for AMPs to penetrate [33,34]. Biofilms, containing a polysaccharide matrix, are communities of
microorganisms attached to a surface [35]. Biofilm-grown cells express several different properties,
such as increased resistance to antimicrobial agents [36]. In the present study, Brevinin-1GHa exhibited
the potent eradication and inhibition on the growth of biofilm against S. aureus, E. coli, and C. albicans.
In summary, a novel peptide Brevinin-1GHa was first isolated from the skin secretion of
H. guentheri. Brevinin-1GHa showed a potent and broad spectrum of antimicrobial activities against
Gram-positive bacteria, Gram-negative bacteria, and fungi. It was able to permeabilize the cell
membrane of S. aureus and C. albicans with high concentrations and eradicate biofilms. However, with
the aim of developing Brevinin-1GHa as a new potential antimicrobial drug, the modification should
still be taken into consideration to reduce its hemolytic activity. This study suggests that Brevinin-1GHa
is a promising candidate for the development of new antibiotic drugs and these findings may provide
novel insights into natural antimicrobial drug design.
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4. Materials and Methods
4.1. Acquisition of Skin Secretions
Specimens of the frog H. guentheri (n = 3) were captured from Fujian Province, People’s Republic of
China. The skin secretions were obtained by mild transdermal electrical stimulation and mild massage
on the skin of frogs, which then washed with deionized water. The combined viscous washings were
dissolved in 0.05% (v/v) trifluoroacetic acid (TFA), snap-frozen in liquid nitrogen, lyophilized and
stored at−20 ◦C [6]. The study was carried out according to the guidelines in the UK Animal (Scientific
Procedures) Act 1986, project license PPL 2694, issued by the Department of Health, Social Services
and Public Safety, Northern Ireland. Procedures had been vetted by the IACUC (PPL 2694) of Queen’s
University Belfast, and approved on 1 March 2011.
4.2. Molecular Cloning of an H. guentheri Skin Secretion-Derived cDNA Library
Six milligrams of lyophilized skin secretion were dissolved in 1 mL of cell lysis/binding buffer
(Life technologies, Oslo, Norway). Then according to the manufacturer, the polyadenylated mRNA
was isolated with magnetic oligo-dT beads (Dynal, Merseyside, UK). A SMART-RACE kit (Clontech,
Palo Alto, CA, USA) was utilized to achieve full-length prepropeptide nucleic acid sequence data.
The 3′-RACE reaction employed a nested universal primer (NUP), and a degenerate sense primer
(5′-TAYGARATHGAYAAYMGICC-3′ Y = C + T, R = A + G, H = A + T + C, M = A + C) was also
designed to a conserved segment of the 5′-untranslated region. The PCR cycling program ran under
the following condition: 90 s at 94 ◦C for initial denaturation; 35 cycles, 30 s at 94 ◦C for further
denaturation; 30 s at 61 ◦C for primer annealing and 180 s at 72 ◦C for the extension. PCR products
were analyzed by DNA-gel electrophoresis, purified and cloned by a pGEM-T vector system (Promega
Corporation, Southampton, UK). A BigDye Terminator sequencing kit (Applied Biosystems, Foster
City, CA, USA) was applied for sequencing reactions and the result was analyzed by an automated
ABI 3100 DNA sequence.
4.3. Identification and Structural Analysis of Brevinin-1GHa
Five mg of lyophilized skin secretion of Hylarana guentheri was dissolved in 0.5 mL of
trifluoroacetic acid (TFA)/water and centrifuged at 2500× g for 5 min. Then the supernatant was
pumped to reverse-phase HPLC with the analytical Jupiter C-5 column (250 × 4.6 mm, Phenomenex,
UK) and eluted with a 0–100% linear gradient program from water/TFA (99.95/0.05, v/v) to
acetonitrile/water/TFA (80/19.95/0.05, v/v/v). The whole program ran over 240 min at a flow rate of
1 mL/min. Fractions were collected at 1 min intervals, and all samples were subjected to time-of-flight
mass spectrometry (MALDI-TOF MS) (Voyager DE, Perspective Biosystems, Foster City, CA, USA).
The instrument was calibrated in the range of 1–4 kDa, and the accuracy of mass determinations
was ±0.1%. The fraction which contained peptides with same molecular mass as that predicted from
cloned cDNA, was injected to analyses the primary structure by LCQ-Fleet ion-trap mass spectrometer
(Thermo Fisher Scientific, San Francisco, CA, USA).
4.4. SPPS of the Novel Peptide and Its Analogues
Upon the primary structure of the novel peptide was determined, it was synthesized by
solid-phase Fmoc chemistry using a Tribute automated peptide synthesizer (Protein Technologies,
Tucson, AZ, USA). The amino acid sequence of the novel peptide was FLGAVLKVAGKLVPAAI
CKISKKC, and it was named Brevinin-1GHa. The amino acid sequences of two analogues
were FLGAVLKVAGKLVPAAI and FLGAVLKVCKISKKCAGKLVPAAI, which were named as
Brevinin-1GHb and Brevinin-1GHc respectively. All amino acids were weighed and mixed with
the activator 2-(1H-benzotriazol-1-yl)-1,1,3,3,-tetramethyluronium hexafluorophosphate (HBTU).
Dimethyl-formamide (DMF), N-methylmorpholine (NMM), and piperidine were also applied in
the coupling program. Then the side chain protection groups were cleaved by the mixture composed
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of 94% Trifluoroacetic acid (TFA), 2% 1,2-ethanedithiol (EDT), 2% thioanisole (TIS), and 2% H2O at
room temperature for 2 h with stirring. After cleavage, peptides were washed by diethyl ether and
dissolved in 10 mL of acetonitrile/water/TFA (80/19.95/0.05, v/v/v) for lyophilization. The synthetic
peptides were purified and confirmed by RP-HPLC and MALDI-TOF. Also, secondary structures of
peptides were predicted by several online analysis tools, including HeliQuest and I-TASSER.
4.5. Antimicrobial Assay
Seven microorganisms were involved to detect the antimicrobial activity of three peptides,
including the Gram-positive bacteria Staphylococcus aureus (S. aureus) (NCTC 10788), Enterococcus
faecalis (E. faecalis) (NCTC 12697), methicillin-resistant Staphylococcus aureus (MRSA) (NCTC 12493); the
Gram-negative bacterial Escherichia coli (E. coli) (NCTC 10418), Pseudomonas aeruginosa (P. aeruginosa)
(ATCC 27853), Klebsiella pneumoniae (K. pneumoniae) (ATCC 43816) and the yeast Candida albicans
(C. albicans) (NCYC 1467). All microorganisms were cultured in Mueller Hinton Broth (MHB) at 37 ◦C
overnight and diluted to 5 × 105 CFU/mL before adding to 96-well plates. Peptides were dissolved in
DMSO to achieve the stock with the concentration at 51.2 mM and subsequently double-diluted to get
the concentration of the peptide from 25.6 mM to 0.1 mM. 1 µL of peptide solutions were incubated
with 99 µL cultured bacterial for 18 h at 37 ◦C. The minimal inhibitory concentrations (MICs) were
determined at 550 nm by a Synergy HT plate reader (BioliseBioTek, Winooski, VT, USA). From wells
which had no apparent growth of the microorganisms, 10 µL of solutions were dropped on Mueller
Hinton agar (MHA) plates. MHA plates were cultured at 37 ◦C for 20 h, and the lowest concentrations
with no colonies were the minimal bactericidal concentrations (MBCs).
4.6. Hemolytic Assay
A 2% (v/v) suspension of erythrocytes was prepared from prewashed defibrinated horse blood
(TCS Biosciences Ltd., Buckingham, UK). Different concentrations of peptides from 512 µM to 1 µM
were incubated with erythrocytes at 37 ◦C for 2 h. PBS in equal volumes was added as negative
controls and 2% of the non-ionic detergent, Triton X-100 (Sigma-Aldrich, St. Louis, MO, USA), was
added as positive controls.
4.7. Time-Killing Assay
S. aureus, E. coli, and C. albicans were cultured overnight in MHB medium to detect the time-killing
curve. Three concentrations used of peptide Brevinin-1GHa were 4×, 2×, and 1× MIC, the MIC
value was according to the results of antimicrobial assays. Bacterial and fungi were diluted with
peptide-treated MHB to a concentration of 5 × 105 CFU/mL. Growing bacterial and fungi were
removed at specified time points and diluted to calculate the colonies.
4.8. Cell Membrane Permeability Assay
The membrane permeability assay was carried out by SYTOX Green Nucleic Acid Stain (Life
technologies, Carlsbad, CA, USA). S. aureus, E. coli, and C. albicans were incubated in MHB at 37 ◦C
overnight. S. aureus and C. albicans were subcultured in TSB, while E. coli was subcultured in LB. All
of them were incubated at 37 ◦C for 2.5 h to achieve the logarithmic growth phase. Then cells were
centrifuged and re-suspended in 5% TSB in 0.85% NaCl solution. 40 µL of peptide solutions with
the concentration at 4×, 2×, and 1× MIC were incubated with 50 µL of cells suspension (1 × 107
CFU/mL) for 2 h at 37 ◦C. Cells treated with 70% isopropanol were applied as positive controls, while
5% TSB were added as the negative control. After incubation, 10 µL SYTOX green was added into
each well to achieve the final concentration at 5 µM. Plates were covered with tinfoil and incubated for
10 min. The fluorescent intensity was recorded by an ELISA plate reader (BioliseBioTek EL808) with
excitation at 485 nm and emission at 528 nm.
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4.9. Anti-Biofilm Assay
The anti-biofilm activities of Brevinin-1GHa were tested on S. aureus, E. coli, and C. albicans.
All microorganisms were incubated in MHB overnight at 37 ◦C and subcultured, while S. aureus, E.
coli, and C. albicans were diluted and cultured in tryptic soy broth (TSB), luria broth (LB), and 1640
medium respectively. For measuring the minimum biofilm inhibitory concentration (MBIC), peptide
solutions from 1–512 µM (1 µL) were incubated with 5 × 105 CFU/mL of bacterial or fungi (99 µL) in
flat-bottomed 96-wells plates for 24 h. For measuring the minimum biofilm eradication concentration
(MBEC), 100 µL of bacterial and fungi were added to the plates without peptides and incubated for
48 h. Until the biofilm formed, plates were washed by PBS and incubated with peptide solutions
from 1–512 µM for 24 h. After incubation, all wells were washed by PBS and fixed by methanol for
30 min at room temperature. 0.1% Crystal Violet was used for staining and, 30% glacial acetic was
used to dissolve the crystal after drying. The absorbance of each well was measured at 595 nm using
the Synergy HT plate reader.
4.10. Statistical Analysis
Data were subjected to statistical analysis using Prism (Version 6.0; GraphPad Software Inc.,
San Diego, CA, USA). Error bars in the graphs represent standard error of the mean (SEM) with
experiments performed on more than three sets of replicates.
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